# OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

Study · id `cardio:ct-nct01182493` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01182493](<https://clinicaltrials.gov/study/NCT01182493>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01182493

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.

## Technical summary

Registry record NCT01182493. Randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2016-03-15.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 331 participants (enrolled count; ClinicalTrials.gov record NCT01182493, source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01182493, source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)
- Primary completion: 2014-02 (actual) (ClinicalTrials.gov record NCT01182493, source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)
- Completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01182493, source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)
- Results first posted: 2016-03-15 (ClinicalTrials.gov record NCT01182493, source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)
- Countries: United States; Austria; Canada; France; Germany; Hungary; Israel; Italy; Netherlands; North Macedonia; Serbia; South Africa; Spain (ClinicalTrials.gov record NCT01182493, source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01182493-2018-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
- Acronym: OpT2mise
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Lead sponsor: Medtronic MiniMed, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Medtronic MiniMed, Inc. (`cardio:org-medtronic-minimed-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial (`cardio:pubmed-24998009`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial (`cardio:pubmed-28374511`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction (`cardio:pubmed-29215299`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1f911913b9896fe807b7e5549e6fc482c426b65460d5e14bb45b2256fb8cf971
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
